Journal of Psychoactive Drugs
2024
Julia M.k. Freind, Fernando R. Beserra, Bruno S Menezes et al.
9 citations
Depression is one of the most prevalent mental health disorders globally, causing severe emotional suffering, reducing life expectancy and increasing the risk of suicide. Recently, the use of dissociative psychedelic substances such as ketamine and esketamine for depressive disorders has expanded treatment options. We sought to analyze, through a systematic review, the existing protocols for...
Frontiers in Psychiatry
2024
Alexandros Matsingos, Marcel Wilhelm, Laila Noor et al.
18 citations
Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials...
Brain Stimulation
2024
Charles R Conway, Scott T Aaronson, Harold A Sackeim et al.
16 citations
RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs),...
Frontiers in Psychiatry
2024
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al.
4 citations
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among individuals with BPD reaches over 80%. The comorbidity of MDD and BPD is associated with more severe depressive symptoms and functional impairment, higher risk of treatment resistance and increased suicidality. The effectiveness of ketamine usage in...
Neuropsychiatric Disease and Treatment
2024
Xuemeng Chen, Rui Zhou, Lan Lan et al.
4 citations
Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different...
Frontiers in Psychiatry
2024
Haixia Chen, Xinxin Zhao, Xinxu Ma et al.
9 citations
Mounting evidence has identified the rapid and sustained antidepressive and anxiolytic-like effects of esketamine. However, the underlying mechanism of this no-monoamine target rapid-onset antidepressant is still underexplored. Immune-inflammatory pathways and cell-mediated immune activation, mainly including inflammatory cytokines in plasma, play a pivotal role in the pathogenesis of major...
Frontiers in Psychiatry
2024
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca et al.
31 citations
Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many...
Frontiers in Pharmacology
2024
Ruixue Liu, Chunxiao Liu, Dianwei Feng et al.
5 citations
Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database between 2019 Q1 and 2023 Q4. Reporting odds ratio (ROR), proportional reporting ratio (PRR), and multi-item gamma Poisson shrinker (MGPS) were...
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
2024
Bixin Huang, Xiaoling Li, Yuling Zheng et al.
4 citations
The present study utilized the spared nerve injury (SNI) to create a mouse model of depression to investigate the impact of esketamine on depressive-like behaviors, on the expression of PSD-95 and CRMP2 proteins, and on changes in neuronal dendritic spine plasticity in the prefrontal cortex (PFC). Depressive-like behavioral tests were performed 1 h after esketamine treatment, and the PFC...
General Hospital Psychiatry
2024
Mina Ansari, Brian Pittman, Daniel S Tylee et al.
6 citations
This study aimed to examine blood pressure changes during ketamine infusion for depression and exploring the factors associated with these changes. This study is a retrospective chart-review of patients with depression undergoing ketamine infusion at Yale Psychiatry Hospital during a 7-year period. Blood pressure (BP) was recorded every 10 min during the infusion. Surges in systolic and...